News

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

Jan 8, 2021

IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

IDL Biotech announced it has signed an agreement with Beckman Coulter for licensing IDL’s entire range of manual ELISA tumor markers. The licensing agreement provides Beckman Coulter with global sales rights and enables IDL to sell material for production and to receive royalties. The agreement has been formally countersigned by Immunotech, a Beckman Coulter subsidiary.

The tumor markers included in the ELISA platform are TPS®, TPAcyk™, MonoTotal® and UBC®.

Read the full press release here (Swedish)

Healthcare day 2026

Apr 16, 2026 | ,

On April 14, IDL participated at Redeye Healthcare Day. CEO Anders Hultman presented the company and shared more about its strategy, current and future markets, and our joint venture with concile. Watch the presentation here

read more

CACLP and meeting with new distributor

Mar 27, 2026 | ,

During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...

read more

Partnership Meetings and CLIA Focus in China

Mar 20, 2026 | ,

Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...

read more